Market Closed - Nasdaq 04:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
1.21 USD -1.63% Intraday chart for Beyond Air, Inc. -6.92% -38.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year 2025 CI
Transcript : Beyond Air, Inc., Q3 2024 Earnings Call, Feb 12, 2024
Earnings Flash (XAIR) BEYOND AIR Posts Q3 Revenue $391,000, vs. Street Est of $0.45M MT
North American Morning Briefing : Stock Futures Steady as Traders Await CPI Data DJ
Beyond Air Affiliate Says First Group Cleared in Phase 1 UNO Study in Solid Tumors; Shares Rise MT
Beyond Air Insider Bought Shares Worth $1,962,000, According to a Recent SEC Filing MT
Truist Cuts Beyond Air's Price Target to $10 From $14, Maintains Buy Rating MT
Beyond Air, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Transcript : Beyond Air, Inc., Q2 2024 Earnings Call, Nov 13, 2023
Earnings Flash (XAIR) BEYOND AIR Reports Q2 Revenue $239,000, vs. Street Est of $482,000 MT
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year Ending March 31, 2025 CI
Beyond Air, Inc. Receives Innovative Technology Contract from Vizient for LungFit PH CI
EARNINGS: Andrews Sykes revenue up; Safestay optimistic AN
Beyond Air, Inc. Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder CI
Beyond Air, Inc. and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region CI
Insider Buy: Beyond Air MT
Beyond Air Files Shelf on Behalf of Selling Stockholders MT
Beyond Air, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Transcript : Beyond Air, Inc., Q1 2024 Earnings Call, Aug 10, 2023
Earnings Flash (XAIR) BEYOND AIR Posts Q1 Revenue $59,000, vs. Street Est of $0.34M MT
Beyond Air Says Preclinical Data Showed Potential of Nitric Oxide in Autism Spectrum Disorder Treatment MT
Beyond Air, Inc. Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder CI
Piper Sandler Starts Beyond Air at Overweight With $10 Price Target MT
Truist Adjusts Beyond Air's Price Target to $14 From $18, Keeps Buy Rating MT
Chart Beyond Air, Inc.
More charts
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.21 USD
Average target price
13 USD
Spread / Average Target
+974.38%
Consensus
  1. Stock Market
  2. Equities
  3. XAIR Stock
  4. News Beyond Air, Inc.
  5. Ladenburg Thalmann Adjusts Beyond Air's Price Target to $23 From $17, Reiterates Buy Rating